Lonsurf
Payments companies reported to CMS as associated with Lonsurf. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lonsurf, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lonsurf
These are the largest totals companies reported as associated with Lonsurf. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Morse | Durham, NC | Hematology & Oncology | $131,516.73 |
| Putao Cen | Houston, TX | Medical Oncology | $71,656.50 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $63,438.27 |
| Ben George | Rochester, MN | Medical Oncology | $60,842.85 |
| John Marshall | Washington, DC | Hematology & Oncology | $43,954.70 |
| Jason Salganick | Phoenix, AZ | Medical Oncology | $37,045.36 |
| Ahmed Zakari | Altamonte Springs, FL | Hematology (Internal Medicine) | $36,286.01 |
| Dai Chu Luu | Dallas, TX | Hematology & Oncology | $26,467.80 |
| Daniel Efiom-Ekaha | York, PA | Hematology & Oncology | $19,452.97 |
| Saurin Chokshi | Memphis, TN | Hematology & Oncology | $16,957.61 |
Prescribed Lonsurf?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.